ARGX vs. BBIO: argenx vs. BridgeBio Pharma Stock Comparison

November 11, 2026

How do argenx (ARGX) and BridgeBio Pharma (BBIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and BridgeBio Pharma (BBIO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

BridgeBio Pharma (BBIO) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for argenx (ARGX) and BridgeBio Pharma (BBIO)
Profile Item	ARGX	BBIO
Name	argenx SE American Depositary Receipt	BridgeBio Pharma Inc.
Country/Region	Netherlands	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	58.31 billion USD	14.47 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	May 18, 2017	June 27, 2019
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

ARGX

BBIO

GSPC

argenx (ARGX) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for argenx (ARGX) and BridgeBio Pharma (BBIO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for argenx (ARGX) and BridgeBio Pharma (BBIO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and BridgeBio Pharma (BBIO)
Metric	ARGX	BBIO
Total Return (1Y)	11.91%	22.70%
Total Return (3Y, Annualized)	25.68%	40.97%
Total Return (5Y, Annualized)	24.22%	8.25%

Risk Profile

Drawdown History

ARGX

BBIO

GSPC

argenx (ARGX) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for argenx (ARGX) and BridgeBio Pharma (BBIO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and BridgeBio Pharma (BBIO)
Metric	ARGX	BBIO
Volatility (1Y, Annualized)	37.87%	44.39%
Beta (5Y)	0.45	0.93
Max Drawdown (5Y)	-38.20%	-89.79%
Avg. Volume (3M)	359.84K	2.68M

Risk-Adjusted Performance

Risk-Return Positioning

ARGX and BBIO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and BridgeBio Pharma (BBIO)
Metric	ARGX	BBIO
Sharpe Ratio (1Y)	0.20	0.41
Sortino Ratio (1Y)	0.31	0.63

Profitability

ROE (TTM)

Neither argenx (ARGX) nor BridgeBio Pharma (BBIO) reports a ROE value for this period, so a direct comparison isn’t possible.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ARGX: --

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
BBIO: --

argenx (ARGX) vs. BridgeBio Pharma (BBIO): Neither stock reports ROE, so the chart shows available benchmark boxes without value markers.

Net Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile argenx (ARGX) reports 31.73%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX: 31.73%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
BBIO: -59.84%

argenx (ARGX) vs. BridgeBio Pharma (BBIO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile argenx (ARGX) reports 36.27%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max: 83.12%
ARGX: 36.27%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
BBIO: -3.30%
Q1: -78.82%
Min: -207.40%

argenx (ARGX) vs. BridgeBio Pharma (BBIO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and BridgeBio Pharma (BBIO)
Metric	ARGX	BBIO
ROE (TTM)	--	--
ROA (TTM)	--	-13.97%
Net Margin (TTM)	31.73%	-59.84%
Operating Margin (TTM)	36.27%	-3.30%
Gross Margin (TTM)	59.84%	94.34%

Growth

Revenue Growth

Both argenx (ARGX) at 89.64% and BridgeBio Pharma (BBIO) at 126.26% sit in the top peer quartile for revenue growth, so each is growing its top line faster than typical industry peers.

argenx (ARGX) vs. BridgeBio Pharma (BBIO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

argenx (ARGX) vs. BridgeBio Pharma (BBIO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and BridgeBio Pharma (BBIO)
Metric	ARGX	BBIO
Revenue Growth (YoY)	89.64%	126.26%
Revenue Growth (3Y CAGR)	116.25%	86.30%
EPS Growth (YoY)	53.13%	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: BridgeBio Pharma (BBIO) shows current ratio of 2.09 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10
ARGX: --

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BBIO: 2.09
Min: 0.10

argenx (ARGX) vs. BridgeBio Pharma (BBIO): ARGX does not report current ratio, so it has no value marker; BBIO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: argenx (ARGX) carries debt-to-equity ratio of 0.01 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
ARGX: 0.01
Min: 0.00

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
BBIO: --

argenx (ARGX) vs. BridgeBio Pharma (BBIO): BBIO does not report debt-to-equity ratio, so it has no value marker; ARGX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and BridgeBio Pharma (BBIO)
Metric	ARGX	BBIO
Current Ratio (MRQ)	--	2.09
Debt / Equity (MRQ)	0.01	--
Net Debt / EBITDA	-2.70	--

Dividends

Dividend Yield (TTM)

Neither argenx (ARGX) nor BridgeBio Pharma (BBIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

argenx (ARGX) vs. BridgeBio Pharma (BBIO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither argenx (ARGX) nor BridgeBio Pharma (BBIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

argenx (ARGX) vs. BridgeBio Pharma (BBIO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and BridgeBio Pharma (BBIO)
Metric	ARGX	BBIO
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max: 85.34
Q3: 43.46
ARGX: 32.12
Median: 26.69
Q1: 13.30
Min: 0.07

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
BBIO: --

argenx (ARGX) vs. BridgeBio Pharma (BBIO): BBIO does not report P/E ratio, so it has no value marker; ARGX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both argenx (ARGX) at 9.86 and BridgeBio Pharma (BBIO) at 15.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max: 58.18
Q3: 25.77
ARGX: 9.86
Median: 7.30
Q1: 3.01
Min: 0.01

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max: 58.18
Q3: 25.77
BBIO: 15.31
Median: 7.30
Q1: 3.01
Min: 0.01

argenx (ARGX) vs. BridgeBio Pharma (BBIO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile argenx (ARGX) reports 172.23, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX: 172.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
BBIO: -5.59
Min: -5.59

argenx (ARGX) vs. BridgeBio Pharma (BBIO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and BridgeBio Pharma (BBIO)
Metric	ARGX	BBIO
P/E Ratio (TTM)	32.12	--
P/S Ratio (TTM)	9.86	15.31
P/B Ratio (MRQ)	172.23	-5.59
Free Cash Flow Yield (TTM)	--	-1.98%